Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Small hands-on Python projects help young learners understand loops, variables, and logic naturally through play. Instant on-screen results maintain motivation and make coding feel rewarding rather ...

Passwords play a huge role in how you stay safe online. They protect your accounts, devices and money. Still, many people pick logins that criminals can guess in seconds. The latest NordPass report ...

Python has become one of the most popular programming languages out there, particularly for beginners and those new to the hacker/maker world. Unfortunately, while it’s easy to get something up and ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Trump’s latest speech included a confusing word mix-up that quickly caught the internet’s attention. Memes and jokes spread rapidly following the viral moment. Coach John Beam dies after being shot on ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...